Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Tarlock, Katherine; Chang, Bill; Cooper, Todd; Gross, Thomas; Gupta, Sumit; Neudorf, Steven; Adlard, Kathleen; Ho, Phoenix A; McGoldrick, Suzanne; Watt, Tanya; Templeman, Tina; Sisler, India; Garee, Amy; Thomson, Blythe; Woolfrey, Ann; Estey, Elihu; Meshinchi, Soheil; Pollard, Jessica A.
Pediatr Blood Cancer
; 62(6): 1048-54, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25662999
[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia.
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.